Effectiveness of Thyme Honey in Management of Xerostomia in Post Radiation Cancer Patients

Sponsor
Ain Shams University (Other)
Overall Status
Completed
CT.gov ID
NCT05859711
Collaborator
(none)
28
1
2
3.9
7.1

Study Details

Study Description

Brief Summary

Xerostomia is the most frequent complication among patients who receive radiotherapy (RT) . The prevalence of xerostomia has been reported to be from 73.5% to 93% (Kakoei S.,2012). Damage to normal tissues can result by radiotherapy as it is not selective to cancer cells, and so affecting the quality of life of patients. Honey is one of the methods studied by CIM for management of HNC treatment side effects due to its properties. (Brennan et al., 2002; Clarkson et al., 2007; Furness et al., 2011;Hackett et al., 2015).

Thyme honey is a new alternative for management of xerostomia, which is a propolis gel product. Thyme honey is a variety of monofloral honey made from the nectar and pollen of thyme flowers. It has a strong antioxidant, antibacterial, antifungal and immuno modulating health effects. Due to the high sugar concentration in honey, it is believed that its presence in the oral cavity has a sialogogue effect, stimulating the salivary glands to produce saliva.

Condition or Disease Intervention/Treatment Phase
  • Drug: thyme honey mouth rinse
  • Drug: saline mouth rinse
Phase 4

Detailed Description

28 post radiation cancer patients were randomly assigned into two equal groups.The intervention group will have oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy. Patients in the control arm followed the same protocol with normal saline rinses. The treatment assessment of subjective dry mouth score, objective dry mouth score, salivary Ph and salivary flow rate will be carried out at baseline, 2 weeks and one month after starting of the treatment protocol (Charalambous et al., 2017).

Nitric oxide levels will be measured at baseline and after one month of treatment (Abadi et al., 2020).

Study Design

Study Type:
Interventional
Actual Enrollment :
28 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effectiveness of Thyme Honey in Management of Xerostomia in Post Radiation Cancer Patients A Randomized Controlled Clinical Trial With a Biochemical Assessment
Actual Study Start Date :
Feb 20, 2021
Actual Primary Completion Date :
Jun 20, 2021
Actual Study Completion Date :
Jun 20, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: thyme honey

oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy. (Charalambous et al.,2017)

Drug: thyme honey mouth rinse
oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy. (Charalambous et al.,2017)

Active Comparator: Saline

oral rinses with saline 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy.

Drug: saline mouth rinse
saline mouth rinse 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy

Outcome Measures

Primary Outcome Measures

  1. subjective dry mouth score [change from baseline at 4 weeks]

    Q1. Do you feel dryness in your mouth ? Q2. Do you drink liquids to help you swallow dry food? Q3. Do you feel mouth dryness when eating a meal? Q4. Does the saliva seem to be too little in your mouth? Subjects who answered confirmatively to at least one of those questions related to dry mouth will be considered as positive for oral dryness subjective complaints.

Secondary Outcome Measures

  1. objective dry mouth score [change from baseline at 4 weeks]

    Objective dry mouth score: The patients will be examined for their signs of dry mouth including: (Osailan et al., 2011). pooled saliva loss stickiness of mouth mirror to buccal mucosa stringy or foamy appearance of saliva dehydration of the lips no response to parotid stimulation Calculation of Objective dry mouth scores will be according to the number of dry mouth signs observed (0-5) and patients with less than 2 score will be excluded

  2. salivary PH [change from baseline at 4 weeks]

    identification of PH according to the color of the PH paper

  3. nitric oxide levels [change from baseline at 4 weeks]

    assessment of nitric oxide levels in the salivary samples using ELISA

  4. Salivary flow rate [change from baseline at 4 weeks]

    assessing unstimulated salivary flow rate in 5 minutes

Eligibility Criteria

Criteria

Ages Eligible for Study:
25 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients referred to non-palliative head and neck radiotherapy

  • Total dose of radiation received (50-70 Gy)

  • Patients with complaint of xerostomia

  • Age 25-65 years old

  • Objective dry mouth score from ( 2-5)

  • Subjective dry mouth score from (1-4)

  • Undergoing radiotherapy for at least three weeks

  • Can independently complete the questionnaire

Exclusion Criteria:
  • Have confirmed systemic diseases or medications associated with xerostomia

  • Have a known allergy to honey

  • Patients who had salivary glands removal surgery

  • Patients with salivary gland diseases or malignancy

  • Vulnerable groups such as pregnant females, prisoners, mentally and physically handicapped individuals.

Contacts and Locations

Locations

Site City State Country Postal Code
1 faculty of dentistry- Ain shams university Cairo Egypt

Sponsors and Collaborators

  • Ain Shams University

Investigators

  • Study Director: Susan Seif, professor, faculty of dentistry- Ain Shams university

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dina Magdi, teaching assistant of oral medicine and periodontology, Ain Shams University
ClinicalTrials.gov Identifier:
NCT05859711
Other Study ID Numbers:
  • FDASU-REC 111
First Posted:
May 16, 2023
Last Update Posted:
May 16, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Dina Magdi, teaching assistant of oral medicine and periodontology, Ain Shams University
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 16, 2023